SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

BioMarin Pharmaceutical Inc. – ‘10-K’ for 12/31/23 – ‘EX-97.1’

On:  Monday, 2/26/24, at 1:34pm ET   ·   For:  12/31/23   ·   Accession #:  1048477-24-16   ·   File #:  0-26727

Previous ‘10-K’:  ‘10-K’ on 2/27/23 for 12/31/22   ·   Latest ‘10-K’:  This Filing   ·   26 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size

 2/26/24  BioMarin Pharmaceutical Inc.      10-K       12/31/23  114:12M

Annual Report   —   Form 10-K   —   SEA’34

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML   2.45M 
 2: EX-21.1     Subsidiaries List                                   HTML     34K 
 3: EX-23.1     Consent of Expert or Counsel                        HTML     32K 
 7: EX-97.1     Clawback Policy re: Recovery of Erroneously         HTML     52K 
                Awarded Compensation                                             
 4: EX-31.1     Certification -- §302 - SOA'02                      HTML     37K 
 5: EX-31.2     Certification -- §302 - SOA'02                      HTML     37K 
 6: EX-32.1     Certification -- §906 - SOA'02                      HTML     34K 
13: R1          Cover Page                                          HTML     99K 
14: R2          Audit Information                                   HTML     38K 
15: R3          Consolidated Balance Sheets                         HTML    135K 
16: R4          Consolidated Balance Sheets (Parenthetical)         HTML     43K 
17: R5          Consolidated Statements of Operations               HTML    112K 
18: R6          Consolidated Statements of Comprehensive Income     HTML     67K 
                (Loss)                                                           
19: R7          Consolidated Statements of Comprehensive Income     HTML     40K 
                (Loss) (Parenthetical)                                           
20: R8          Consolidated Statements of Stockholders' Equity     HTML     80K 
21: R9          Consolidated Statements of Cash Flows               HTML    147K 
22: R10         Business Overview and Significant Accounting        HTML     98K 
                Policies                                                         
23: R11         Financial Instruments                               HTML    109K 
24: R12         Intangible Assets                                   HTML     53K 
25: R13         Property, Plant and Equipment                       HTML     50K 
26: R14         Inventory                                           HTML     41K 
27: R15         Supplemental Financial Statement Information        HTML     70K 
28: R16         Fair Value Measurements                             HTML     92K 
29: R17         Derivative Instruments and Hedging Strategies       HTML     75K 
30: R18         Leases                                              HTML     96K 
31: R19         Debt                                                HTML     69K 
32: R20         Accumulated Other Comprehensive Income (Loss)       HTML     65K 
33: R21         Revenue, Credit Concentrations and Geographic       HTML     88K 
                Information                                                      
34: R22         Equity Compensation Plans and Stock-Based           HTML    118K 
                Compensation                                                     
35: R23         Other Employee Benefits                             HTML     38K 
36: R24         Income Taxes                                        HTML    122K 
37: R25         Earnings (Loss) Per Common Share                    HTML     58K 
38: R26         License and Collaboration Agreements                HTML     40K 
39: R27         Commitments and Contingencies                       HTML     42K 
40: R28         Pay vs Performance Disclosure                       HTML     45K 
41: R29         Insider Trading Arrangements                        HTML     67K 
42: R30         Business Overview and Significant Accounting        HTML    154K 
                Policies (Policies)                                              
43: R31         Business Overview and Significant Accounting        HTML     39K 
                Policies (Tables)                                                
44: R32         Financial Instruments (Tables)                      HTML    106K 
45: R33         Intangible Assets (Tables)                          HTML     58K 
46: R34         Property, Plant and Equipment (Tables)              HTML     49K 
47: R35         Inventory (Tables)                                  HTML     42K 
48: R36         Supplemental Financial Statement Information        HTML     70K 
                (Tables)                                                         
49: R37         Fair Value Measurements (Tables)                    HTML     93K 
50: R38         Derivative Instruments and Hedging Strategies       HTML     79K 
                (Tables)                                                         
51: R39         Leases (Tables)                                     HTML    120K 
52: R40         Debt (Tables)                                       HTML     62K 
53: R41         Accumulated Other Comprehensive Income (Loss)       HTML     64K 
                (Tables)                                                         
54: R42         Revenue, Credit Concentrations and Geographic       HTML     93K 
                Information (Tables)                                             
55: R43         Equity Compensation Plans and Stock-Based           HTML    116K 
                Compensation (Tables)                                            
56: R44         Income Taxes (Tables)                               HTML    126K 
57: R45         Earnings (Loss) Per Common Share (Tables)           HTML     60K 
58: R46         BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING        HTML     59K 
                POLICIES - Narrative (Details)                                   
59: R47         BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING        HTML     51K 
                POLICIES - Schedule of Property, Plant and                       
                Equipment Estimated Useful Lives (Details)                       
60: R48         FINANCIAL INSTRUMENTS - Schedule of Cash, Cash      HTML     92K 
                Equivalents and Available-for-Sale Securities by                 
                Significant Investment Category (Details)                        
61: R49         FINANCIAL INSTRUMENTS - Narrative (Details)         HTML     40K 
62: R50         INTANGIBLE ASSETS - Schedule of Intangible Assets,  HTML     40K 
                Net (Details)                                                    
63: R51         INTANGIBLE ASSETS - Schedule of Carrying Value and  HTML     45K 
                Estimated Remaining Life of Finite-Lived                         
                Intangible Assets (Details)                                      
64: R52         INTANGIBLE ASSETS - Schedule of Estimated Future    HTML     48K 
                Amortization Expense (Details)                                   
65: R53         PROPERTY, PLANT AND EQUIPMENT - Schedule of         HTML     64K 
                Property, Plant and Equipment, Net (Details)                     
66: R54         PROPERTY, PLANT AND EQUIPMENT - Narrative           HTML     35K 
                (Details)                                                        
67: R55         Inventory (Details)                                 HTML     42K 
68: R56         SUPPLEMENTAL FINANCIAL STATEMENT INFORMATION -      HTML     55K 
                Schedule of Accounts Payable and Accrued                         
                Liabilities (Details)                                            
69: R57         SUPPLEMENTAL FINANCIAL STATEMENT INFORMATION -      HTML     42K 
                Narrative (Details)                                              
70: R58         SUPPLEMENTAL FINANCIAL STATEMENT INFORMATION -      HTML     45K 
                Schedule of Estimated Accrued Rebates and Reserve                
                for Cash Discounts (Details)                                     
71: R59         FAIR VALUE MEASUREMENTS - Schedule of Financial     HTML     82K 
                Assets and Liabilities Measured at Fair Value                    
                (Details)                                                        
72: R60         FAIR VALUE MEASUREMENTS - Schedule of Liabilities   HTML     42K 
                Measured at Fair Value Using Level 3 Inputs                      
                (Details)                                                        
73: R61         DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES -     HTML     41K 
                Narrative (Details)                                              
74: R62         DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES -     HTML     44K 
                Schedule of Aggregate Notional Amounts Outstanding               
                (Details)                                                        
75: R63         DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES -     HTML     56K 
                Schedule of Fair Value Carrying Amount of                        
                Derivative Instruments (Details)                                 
76: R64         DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES -     HTML     46K 
                Schedule of Impact of Gains and Losses from                      
                Consolidated Statements of Operations (Details)                  
77: R65         LEASES - Schedule of ROU Assets and Lease           HTML     64K 
                Liabilities (Details)                                            
78: R66         LEASES - Schedule of Maturities of Lease            HTML     91K 
                Liabilities (Details)                                            
79: R67         LEASES - Schedule of Lease Cost (Details)           HTML     46K 
80: R68         LEASES - Schedule of Other Information (Details)    HTML     44K 
81: R69         LEASES - Schedule of Supplemental Cash Flow         HTML     48K 
                Information (Details)                                            
82: R70         DEBT - Narrative (Details)                          HTML     84K 
83: R71         DEBT - Schedule of Senior Subordinated Convertible  HTML     65K 
                Obligations (Details)                                            
84: R72         DEBT - Schedule of Interest Expense on Fixed-Rate   HTML     48K 
                Convertible Debt (Details)                                       
85: R73         Accumulated Other Comprehensive Income (LOSS) -     HTML     62K 
                Schedule of Changes in Accumulated Balances of                   
                AOCI Including Current Period Other Comprehensive                
                Income (Loss) and Reclassifications Out of AOCI                  
                (Details)                                                        
86: R74         REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC       HTML     65K 
                INFORMATION - Schedule of Total Revenues and                     
                Disaggregates Net Product Revenues by Product                    
                (Details)                                                        
87: R75         REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC       HTML     60K 
                INFORMATION - Schedule of Disaggregation of Total                
                Net Product Revenues by Geographic Region                        
                (Details)                                                        
88: R76         REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC       HTML     47K 
                INFORMATION - Schedule of Total Net Product                      
                Revenues Attributed to Largest Customers (Details)               
89: R77         REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC       HTML     47K 
                INFORMATION - Narrative (Details)                                
90: R78         REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC       HTML     41K 
                INFORMATION - Schedule of Long-Lived Assets by                   
                Geographic Region (Details)                                      
91: R79         EQUITY COMPENSATION PLANS AND STOCK-BASED           HTML    140K 
                COMPENSATION - Narrative (Details)                               
92: R80         EQUITY COMPENSATION PLANS AND STOCK-BASED           HTML     51K 
                COMPENSATION - Schedule of Stock-Based                           
                Compensation Expense (Details)                                   
93: R81         EQUITY COMPENSATION PLANS AND STOCK-BASED           HTML     73K 
                COMPENSATION - Schedule of Restricted Stock Unit                 
                Activity (Details)                                               
94: R82         EQUITY COMPENSATION PLANS AND STOCK-BASED           HTML     57K 
                COMPENSATION - Schedule of Fair Value of TSR-RSUs                
                Granted Assumptions (Details)                                    
95: R83         EQUITY COMPENSATION PLANS AND STOCK-BASED           HTML     83K 
                COMPENSATION - Schedule of Stock Option Activity                 
                (Details)                                                        
96: R84         EQUITY COMPENSATION PLANS AND STOCK-BASED           HTML     60K 
                COMPENSATION - Schedule of Fair Value of Stock                   
                Options Granted Assumptions (Details)                            
97: R85         EQUITY COMPENSATION PLANS AND STOCK-BASED           HTML     60K 
                COMPENSATION - Schedule of Fair Value of Stock                   
                Purchase Rights Granted Under the ESPP (Details)                 
98: R86         Other Employee Benefits (Details)                   HTML     40K 
99: R87         INCOME TAXES - Schedule of Provision for (Benefit   HTML     43K 
                from) Income Taxes Based on Income (Loss) Before                 
                Income Taxes (Details)                                           
100: R88         INCOME TAXES - Schedule of Components of Provision  HTML     61K  
                for (Benefit from) Income Taxes (Details)                        
101: R89         INCOME TAXES - Schedule of Reconciliation of        HTML     66K  
                Statutory Federal Income Tax Benefit to Effective                
                Tax Rate (Details)                                               
102: R90         INCOME TAXES - Schedule of Components of Net        HTML     71K  
                Deferred Tax Assets (Details)                                    
103: R91         INCOME TAXES - Schedule of Net Operating Loss and   HTML     46K  
                Tax Credit Carryforwards (Details)                               
104: R92         INCOME TAXES - Narrative (Details)                  HTML     47K  
105: R93         INCOME TAXES - Schedule of Reconciliation of        HTML     43K  
                Unrecognized Tax Benefits (Details)                              
106: R94         Earnings (LOSS) PER COMMON SHARE - Schedule of      HTML     71K  
                Computation of Basic and Diluted Earnings (Loss)                 
                Per Common Share (Details)                                       
107: R95         Earnings (LOSS) PER COMMON SHARE - Schedule of      HTML     49K  
                Anti-Dilutive Common Stock Excluded from                         
                Computation of Basic and Diluted Earnings (Loss)                 
                Per Share (Details)                                              
108: R96         License and Collaboration Agreements (Details)      HTML     71K  
109: R97         Commitments and Contingencies (Details)             HTML     53K  
111: XML         IDEA XML File -- Filing Summary                      XML    215K  
114: XML         XBRL Instance -- bmrn-20231231_htm                   XML   2.84M  
110: EXCEL       IDEA Workbook of Financial Report Info              XLSX    222K  
 9: EX-101.CAL  XBRL Calculations -- bmrn-20231231_cal               XML    338K 
10: EX-101.DEF  XBRL Definitions -- bmrn-20231231_def                XML    925K 
11: EX-101.LAB  XBRL Labels -- bmrn-20231231_lab                     XML   2.67M 
12: EX-101.PRE  XBRL Presentations -- bmrn-20231231_pre              XML   1.59M 
 8: EX-101.SCH  XBRL Schema -- bmrn-20231231                         XSD    256K 
112: JSON        XBRL Instance as JSON Data -- MetaLinks              683±  1.05M  
113: ZIP         XBRL Zipped Folder -- 0001048477-24-000016-xbrl      Zip    724K  


‘EX-97.1’   —   Clawback Policy re: Recovery of Erroneously Awarded Compensation


This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



 C:   C: 
  Document  
Exhibit 97.1
BIOMARIN PHARMACEUTICAL INC.
Dodd-Frank Incentive Compensation Recoupment Policy
(adopted October 4, 2023)
1.Introduction
The Board of Directors (the “Board”) of BioMarin Pharmaceutical Inc., a Delaware corporation (the “Company”), has determined that it is in the best interests of the Company and its stockholders to adopt this Dodd-Frank Incentive Compensation Recoupment Policy (this “Policy”) providing for the Company’s recoupment of Recoverable Incentive Compensation that is received by Covered Officers of the Company under certain circumstances. Certain capitalized terms used in this Policy have the meanings given to such terms in Section 3 below.
This Policy is designed to comply with, and shall be interpreted to be consistent with, Section 10D of the Exchange Act, Rule 10D-1 promulgated thereunder (“Rule 10D-1”) and Nasdaq Listing Rule 5608 (the “Listing Standards”).
2.Effective Date
This Policy shall apply to all Incentive Compensation that is received by a Covered Officer on or after October 2, 2023 (the “Effective Date”). Incentive Compensation is deemed “received” in the Company’s fiscal period in which the Financial Reporting Measure specified in the Incentive Compensation award is attained, even if the payment or grant of such Incentive Compensation occurs after the end of that period.
3.Definitions
Accounting Restatement” means an accounting restatement that the Company is required to prepare due to the material noncompliance of the Company with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements, or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period.
Accounting Restatement Date” means the earlier to occur of (a) the date that the Board, a committee of the Board authorized to take such action, or the officer or officers of the Company authorized to take such action if Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare an Accounting Restatement, or (b) the date that a court, regulator or other legally authorized body directs the Company to prepare an Accounting Restatement.
Administrator” means the Compensation Committee or, in the absence of such committee, the Board.
Code” means the U.S. Internal Revenue Code of 1986, as amended, and the regulations promulgated thereunder.
Compensation Committee” means the Compensation Committee of the Board.
Covered Officer” means each current and former Executive Officer.
Exchange” means the Nasdaq Stock Market.
Exchange Act” means the U.S. Securities Exchange Act of 1934, as amended.
Executive Officer” means the Company’s president, principal financial officer, principal accounting officer (or if there is no such accounting officer, the controller), any vice-president of the Company in charge of a principal business unit, division, or function (such as sales, administration, or finance), any other officer who performs a policy-making function, or any other person who performs similar policy-making functions for the Company. Executive officers of the Company’s parent(s) or subsidiaries are deemed executive officers of the Company if they perform such policy-making functions for the Company. Policy-making function is not intended to include policy-making functions that are not significant. Identification of an executive officer for purposes of this Policy would include at a minimum executive officers identified pursuant to Item 401(b) of Regulation S-K promulgated under the Exchange Act.
Financial Reporting Measures” means measures that are determined and presented in accordance with the accounting principles used in preparing the Company’s financial statements, and any measures derived wholly or in part from such measures, including Company stock price and total stockholder return (“TSR”). A measure need not be presented in the Company’s financial statements or included in a filing with the SEC in order to be a Financial Reporting Measure.
1


Incentive Compensation” means any compensation that is granted, earned or vested based wholly or in part upon the attainment of a Financial Reporting Measure.
Lookback Period” means the three completed fiscal years immediately preceding the Accounting Restatement Date, as well as any transition period (resulting from a change in the Company’s fiscal year) within or immediately following those three completed fiscal years (except that a transition period of at least nine months shall count as a completed fiscal year). Notwithstanding the foregoing, the Lookback Period shall not include fiscal years completed prior to the Effective Date.
Recoverable Incentive Compensation” means Incentive Compensation received by a Covered Officer during the Lookback Period that exceeds the amount of Incentive Compensation that would have been received had such amount been determined based on the Accounting Restatement, computed without regard to any taxes paid (i.e., on a gross basis without regard to tax withholdings and other deductions). For any compensation plans or programs that take into account Incentive Compensation, the amount of Recoverable Incentive Compensation for purposes of this Policy shall include, without limitation, the amount contributed to any notional account based on Recoverable Incentive Compensation and any earnings to date on that notional amount. For any Incentive Compensation that is based on stock price or TSR, where the Recoverable Incentive Compensation is not subject to mathematical recalculation directly from the information in an Accounting Restatement, the Administrator will determine the amount of Recoverable Incentive Compensation based on a reasonable estimate of the effect of the Accounting Restatement on the stock price or TSR upon which the Incentive Compensation was received. The Company shall maintain documentation of the determination of that reasonable estimate and provide such documentation to the Exchange in accordance with the Listing Standards.
SEC” means the U.S. Securities and Exchange Commission.
4.Recoupment
(a)Applicability of Policy. This Policy applies to Incentive Compensation received by a Covered Officer (i) after beginning services as an Executive Officer, (ii) who served as an Executive Officer at any time during the performance period for such Incentive Compensation, (iii) while the Company had a class of securities listed on a national securities exchange or a national securities association, and (iv) during the Lookback Period.
(b)Recoupment Generally. Pursuant to the provisions of this Policy, if there is an Accounting Restatement, the Company must reasonably promptly recoup the full amount of the Recoverable Incentive Compensation, unless the conditions of one or more subsections of Section 4(c) of this Policy are met and the Compensation Committee, or, if such committee does not consist solely of independent directors, a majority of the independent directors serving on the Board, has made a determination that recoupment would be impracticable. Recoupment is required regardless of whether the Covered Officer engaged in any misconduct and regardless of fault, and the Company’s obligation to recoup Recoverable Incentive Compensation is not dependent on whether or when any restated financial statements are filed.
(c)Impracticability of Recovery. Recoupment may be determined to be impracticable if, and only if:
(i)the direct expense paid to a third party to assist in enforcing this Policy would exceed the amount of the applicable Recoverable Incentive Compensation; provided that, before concluding that it would be impracticable to recover any amount of Recoverable Incentive Compensation based on expense of enforcement, the Company shall make a reasonable attempt to recover such Recoverable Incentive Compensation, document such reasonable attempt(s) to recover, and provide that documentation to the Exchange in accordance with the Listing Standards; or
(ii)recoupment of the applicable Recoverable Incentive Compensation would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the Company, to fail to meet the requirements of Code Section 401(a)(13) or Code Section 411(a) and regulations thereunder.
(d)Sources of Recoupment. To the extent permitted by applicable law, the Administrator shall, in its sole discretion, determine the timing and method for recouping Recoverable Incentive Compensation hereunder, provided that such recoupment is undertaken reasonably promptly. The Administrator may, in its discretion, seek recoupment from a Covered Officer from any of the following sources or a combination thereof, whether the applicable compensation was approved, awarded, granted, payable or paid to the Covered Officer prior to, on or after the Effective Date: (i) direct repayment of Recoverable Incentive Compensation previously paid to the Covered Officer; (ii) cancelling prior cash or equity-based awards (whether vested or unvested and whether paid or unpaid); (iii) cancelling or offsetting against any planned future cash or equity-based awards; (iv) forfeiture of deferred compensation, subject to compliance with Code Section 409A; and (v) any other method authorized by applicable law or contract. Subject to compliance with any applicable law, the Administrator may effectuate recoupment under this Policy from any amount otherwise payable to the Covered Officer, including amounts payable to such individual under any otherwise applicable Company plan or program, e.g., base salary, bonuses or commissions and compensation previously deferred by the Covered Officer. The Administrator need not utilize the same method of recovery for all Covered Officers or with respect to all types of Recoverable Incentive Compensation.
2



(e)No Indemnification of Covered Officers. Notwithstanding any indemnification agreement, applicable insurance policy or any other agreement or provision of the Company’s certificate of incorporation or bylaws to the contrary, no Covered Officer shall be entitled to indemnification or advancement of expenses in connection with any enforcement of this Policy by the Company, including paying or reimbursing such Covered Officer for insurance premiums to cover potential obligations to the Company under this Policy.
(f)Indemnification of Administrator. Any members of the Administrator, and any other members of the Board who assist in the administration of this Policy, shall not be personally liable for any action, determination or interpretation made with respect to this Policy and shall be indemnified by the Company to the fullest extent under applicable law and Company policy with respect to any such action, determination or interpretation. The foregoing sentence shall not limit any other rights to indemnification of the members of the Board under applicable law or Company policy.
(g)No “Good Reason” for Covered Officers. Any action by the Company to recoup or any recoupment of Recoverable Incentive Compensation under this Policy from a Covered Officer shall not be deemed (i) “good reason” for resignation or to serve as a basis for a claim of constructive termination under any benefits or compensation arrangement applicable to such Covered Officer, or (ii) to constitute a breach of a contract or other arrangement to which such Covered Officer is party.
5.Administration
Except as specifically set forth herein, this Policy shall be administered by the Administrator. The Administrator shall have full and final authority to make any and all determinations required under this Policy. Any determination by the Administrator with respect to this Policy shall be final, conclusive and binding on all interested parties and need not be uniform with respect to each individual covered by this Policy. In carrying out the administration of this Policy, the Administrator is authorized and directed to consult with the full Board or such other committees of the Board as may be necessary or appropriate as to matters within the scope of such other committee’s responsibility and authority. Subject to applicable law, the Administrator may authorize and empower any officer or employee of the Company to take any and all actions that the Administrator, in its sole discretion, deems necessary or appropriate to carry out the purpose and intent of this Policy (other than with respect to any recovery under this Policy involving such officer or employee).
6.Severability
If any provision of this Policy or the application of any such provision to a Covered Officer shall be adjudicated to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provisions of this Policy, and the invalid, illegal or unenforceable provisions shall be deemed amended to the minimum extent necessary to render any such provision or application enforceable.
7.No Impairment of Other Remedies
Nothing contained in this Policy, and no recoupment or recovery as contemplated herein, shall limit any claims, damages or other legal remedies the Company or any of its affiliates may have against a Covered Officer arising out of or resulting from any actions or omissions by the Covered Officer. This Policy does not preclude the Company from taking any other action to enforce a Covered Officer’s obligations to the Company, including, without limitation, termination of employment and/or institution of civil proceedings. This Policy is in addition to the requirements of Section 304 of the Sarbanes-Oxley Act of 2002 (“SOX 304”) that are applicable to the Company’s Chief Executive Officer and Chief Financial Officer and to any other compensation recoupment policy and/or similar provisions in any employment, equity plan, equity award, or other individual agreement, to which the Company is a party or which the Company has adopted or may adopt and maintain from time to time; provided, however, that compensation recouped pursuant to this Policy shall not be duplicative of compensation recouped pursuant to SOX 304 or any such compensation recoupment policy and/or similar provisions in any such employment, equity plan, equity award, or other individual agreement except as may be required by law.
8.Amendment; Termination
The Administrator may amend, terminate or replace this Policy or any portion of this Policy at any time and from time to time in its sole discretion. The Administrator shall amend this Policy as it deems necessary to comply with applicable law or any Listing Standard.
9.Successors
This Policy shall be binding and enforceable against all Covered Officers and, to the extent required by Rule 10D-1 and/or the applicable Listing Standards, their beneficiaries, heirs, executors, administrators or other legal representatives.
10.    Required Filings
3



    The Company shall make any disclosures and filings with respect to this Policy that are required by law, including as required by the SEC.
*    *    *    *    *
4


Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-K’ Filing    Date    Other Filings
Filed on:2/26/24
For Period end:12/31/235
10/4/234
10/2/23
 List all Filings 


26 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

12/20/23  BioMarin Pharmaceutical Inc.      8-K:1,5,7,912/20/23   12:315K                                   Donnelley … Solutions/FA
11/03/23  BioMarin Pharmaceutical Inc.      8-K:5,9    10/30/23   13:368K                                   Donnelley … Solutions/FA
 8/02/23  BioMarin Pharmaceutical Inc.      10-Q        6/30/23   69:7.5M
 2/27/23  BioMarin Pharmaceutical Inc.      10-K       12/31/22  115:14M
12/21/22  BioMarin Pharmaceutical Inc.      8-K:5,9    12/15/22   11:425K                                   Donnelley … Solutions/FA
10/28/22  BioMarin Pharmaceutical Inc.      10-Q        9/30/22   71:8.1M
 4/29/22  BioMarin Pharmaceutical Inc.      10-Q        3/31/22   68:7.2M
 2/25/22  BioMarin Pharmaceutical Inc.      10-K       12/31/21  117:14M
 5/14/20  BioMarin Pharmaceutical Inc.      8-K:1,2,3,8 5/11/20   13:976K                                   Donnelley … Solutions/FA
 2/27/20  BioMarin Pharmaceutical Inc.      10-K       12/31/19  127:17M
 8/02/19  BioMarin Pharmaceutical Inc.      10-Q        6/30/19   94:11M
11/13/17  BioMarin Pharmaceutical Inc.      10-Q/A      6/30/17    4:252K                                   ActiveDisclosure/FA
 8/11/17  BioMarin Pharmaceutical Inc.      8-K:1,2,8,9 8/07/17    7:1M                                     Donnelley … Solutions/FA
 6/12/17  BioMarin Pharmaceutical Inc.      8-K:5,9     6/06/17    7:254K                                   Donnelley … Solutions/FA
 2/27/17  BioMarin Pharmaceutical Inc.      10-K       12/31/16  132:23M                                    ActiveDisclosure/FA
12/19/16  BioMarin Pharmaceutical Inc.      8-K:1,5,9  12/13/16    3:196K                                   ActiveDisclosure/FA
12/09/16  BioMarin Pharmaceutical Inc.      8-K:5,9    12/05/16    2:46K                                    ActiveDisclosure/FA
 1/07/16  BioMarin Pharmaceutical Inc.      8-K:1,2,9   1/01/16    4:776K                                   Donnelley … Solutions/FA
11/02/15  BioMarin Pharmaceutical Inc.      10-Q        9/30/15  100:16M                                    ActiveDisclosure/FA
 6/15/15  BioMarin Pharmaceutical Inc.      8-K:5,9     6/09/15    4:379K                                   Donnelley … Solutions/FA
10/14/14  BioMarin Pharmaceutical Inc.      8-K:5,9    10/07/14    3:254K                                   Donnelley … Solutions/FA
 5/16/13  Biomarin Pharmaceutical Inc.      8-K:5,9     5/14/13    2:49K                                    Donnelley … Solutions/FA
 8/02/12  Biomarin Pharmaceutical Inc.      10-Q        6/30/12   80:7.5M                                   Donnelley … Solutions/FA
 2/28/08  Biomarin Pharmaceutical Inc.      10-K       12/31/07   11:2M                                     Donnelley … Solutions/FA
 3/16/05  Biomarin Pharmaceutical Inc.      10-K       12/31/04   18:2M                                     Donnelley … Solutions/FA
 7/06/99  Biomarin Pharmaceutical Inc.      S-1/A                  5:500K                                   Donnelley Fin’l S… 13/FA
Top
Filing Submission 0001048477-24-000016   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Tue., Apr. 30, 6:51:45.2pm ET